PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions.
Immunotherapy
Lung cancer
PET
Radiation oncology
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
23
10
2020
accepted:
18
01
2021
pubmed:
25
3
2021
medline:
21
10
2021
entrez:
24
3
2021
Statut:
ppublish
Résumé
The advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced NSCLC, leading to a string of approvals in recent years. Herein, a narrative review on the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in the ever-evolving treatment landscape of advanced NSCLC is presented. This comprehensive review will begin with an introduction into current treatment paradigms incorporating ICIs; the evolution of CT-based criteria; moving onto novel phenomena observed with ICIs and the current state of hybrid imaging for diagnosis, treatment planning, evaluation of treatment efficacy and toxicity in advanced NSCLC, also taking into consideration its limitations and future directions. The advent of ICIs marks the dawn of a new era bringing forth new challenges particularly vis-à-vis treatment response assessment and observation of novel phenomena accompanied by novel systemic side effects. While FDG PET/CT is widely adopted for tumor volume delineation in locally advanced disease, response assessment to immunotherapy based on current criteria is of high clinical value but has its inherent limitations. In recent years, modifications of established (PET)/CT criteria have been proposed to provide more refined approaches towards response evaluation. Not only a comprehensive inclusion of PET-based response criteria in prospective randomized controlled trials, but also a general harmonization within the variety of PET-based response criteria is pertinent to strengthen clinical implementation and widespread use of hybrid imaging for response assessment in NSCLC.
Identifiants
pubmed: 33760957
doi: 10.1007/s00259-021-05211-8
pii: 10.1007/s00259-021-05211-8
pmc: PMC8484219
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3975-3989Informations de copyright
© 2021. The Author(s).
Références
Ettinger DS, Wood DE, Chair V, et al. National Comprehensive Cancer Network. NSCLC (Version 3.2020). 2020. https://www.Nccn.Org/Professionals/Physician_gls/Pdf/Nscl.Pdf . Accessed April 30, 2020.
Borcoman E, Kanjanapan Y, Champiat S, et al. Novel patterns of response under immunotherapy. Ann Oncol. 2019;30(3):385–96. https://doi.org/10.1093/annonc/mdz003 .
doi: 10.1093/annonc/mdz003
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707–23. https://doi.org/10.1016/j.cell.2017.01.017 .
doi: 10.1016/j.cell.2017.01.017
pubmed: 28187290
pmcid: 5391692
Kerr KM, Hirsch FR. Programmed death ligand-1 immunohistochemistry: friend or foe? Arch Pathol Lab Med. 2016;140(4):326–31. https://doi.org/10.5858/arpa.2015-0522-SA .
doi: 10.5858/arpa.2015-0522-SA
pubmed: 26756647
Mayer AT, Gambhir SS. The immunoimaging toolbox. J Nucl Med. 2018;59(8):1174–82. https://doi.org/10.2967/jnumed.116.185967 .
doi: 10.2967/jnumed.116.185967
pubmed: 29794226
pmcid: 6071502
Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy: report on the EANM symposium on immune modulation and recent review of the literature. Eur J Nucl Med Mol Imaging. 2019;46(1):238–50. https://doi.org/10.1007/s00259-018-4171-4 .
doi: 10.1007/s00259-018-4171-4
pubmed: 30291373
Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1(9):1325–32. https://doi.org/10.1001/jamaoncol.2015.2756 .
doi: 10.1001/jamaoncol.2015.2756
pubmed: 26270858
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC | NEJM. N Engl J Med. 2019;379:2342–50. https://doi.org/10.1056/NEJMoa1809697 .
doi: 10.1056/NEJMoa1809697
Käsmann L, Eze C, Taugner J, et al. Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiat Oncol. 2020;15(1):167. https://doi.org/10.1186/s13014-020-01595-3 .
doi: 10.1186/s13014-020-01595-3
pubmed: 32646443
pmcid: 7350600
Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58(3):862–70. https://doi.org/10.1016/j.ijrobp.2003.09.012 .
doi: 10.1016/j.ijrobp.2003.09.012
pubmed: 14967443
Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 2016;40(1):25–37. https://doi.org/10.1016/j.currproblcancer.2015.10.001 .
doi: 10.1016/j.currproblcancer.2015.10.001
pubmed: 26582738
Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14(6):365–79. https://doi.org/10.1038/nrclinonc.2016.211 .
doi: 10.1038/nrclinonc.2016.211
pubmed: 28094262
Käsmann L, Eze C, Manapov F. Stereotactic body radiation therapy (SBRT) combined with immune check-point inhibition (ICI) in advanced lung cancer: which metastatic site should be irradiated to induce immunogenic cell death? Int J Radiat Oncol Biol Phys. 2020;108(1):225–6. https://doi.org/10.1016/j.ijrobp.2020.04.002 .
doi: 10.1016/j.ijrobp.2020.04.002
pubmed: 32414625
Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–82. https://doi.org/10.1016/S1470-2045(16)30532-0 .
doi: 10.1016/S1470-2045(16)30532-0
pubmed: 27789196
pmcid: 5143183
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–8. https://doi.org/10.1016/S0140-6736(18)32487-5 .
doi: 10.1016/S0140-6736(18)32487-5
pubmed: 30982687
Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med. 2019;381(21):2020–31. https://doi.org/10.1056/NEJMoa1910231 .
doi: 10.1056/NEJMoa1910231
pubmed: 31562796
Spigel D, de Marinis F, Giaccone G, et al. LBA78 - IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. Ann Oncol. 2019;30:v915. https://doi.org/10.1093/annonc/mdz293 .
doi: 10.1093/annonc/mdz293
Reck M, Ciuleanu T-E, Dols MC, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. J Clin Oncol. 2020;38(15_suppl):9501. https://doi.org/10.1200/jco.2020.38.15_suppl.9501 .
doi: 10.1200/jco.2020.38.15_suppl.9501
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–14. https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6 .
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. JNCI J Natl Cancer Inst. 2000;92(3):205–16. https://doi.org/10.1093/jnci/92.3.205 .
doi: 10.1093/jnci/92.3.205
pubmed: 10655437
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026 .
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20. https://doi.org/10.1158/1078-0432.CCR-09-1624 .
doi: 10.1158/1078-0432.CCR-09-1624
pubmed: 19934295
Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res. 2013;19(14):3936–43. https://doi.org/10.1158/1078-0432.CCR-13-0895 .
doi: 10.1158/1078-0432.CCR-13-0895
pubmed: 23743568
pmcid: 3740724
Bohnsack O, Hoos A, Ludajic K. Adaptation of the immune related response criteria: irrecist. Ann Oncol. 2014;25:iv369. https://doi.org/10.1093/annonc/mdu342.23 .
doi: 10.1093/annonc/mdu342.23
Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–52. https://doi.org/10.1016/S1470-2045(17)30074-8 .
doi: 10.1016/S1470-2045(17)30074-8
pubmed: 28271869
pmcid: 5648544
Stephen Hodi F, Ballinger M, Lyons B, et al. Immune-modified response evaluation criteria in solid tumors (imrecist): refining guidelines to assess the clinical benefit of cancer immunotherapy. J Clin Oncol. 2018;36(9):850–8. https://doi.org/10.1200/JCO.2017.75.1644 .
doi: 10.1200/JCO.2017.75.1644
pubmed: 29341833
Unterrainer M, Ruzicka M, Fabritius MP, et al. PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. Eur Radiol Exp. 2020;4(1):63. https://doi.org/10.1186/s41747-020-00190-1 .
Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675–84. https://doi.org/10.1200/JCO.2017.77.0412 .
doi: 10.1200/JCO.2017.77.0412
pubmed: 29570421
Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541–3. https://doi.org/10.1200/jco.2015.61.6870 .
doi: 10.1200/jco.2015.61.6870
pubmed: 26261262
pmcid: 4622096
Goldfarb L, Duchemann B, Chouahnia K, Zelek L, Soussan M. Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. EJNMMI Res. 2019;9(1):8. https://doi.org/10.1186/s13550-019-0473-1 .
doi: 10.1186/s13550-019-0473-1
pubmed: 30694399
pmcid: 6890907
Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 2018;4(11):1543–52. https://doi.org/10.1001/jamaoncol.2018.3676 .
doi: 10.1001/jamaoncol.2018.3676
pubmed: 30193240
pmcid: 6248085
Kas B, Talbot H, Ferrara R, et al. Clarification of definitions of hyperprogressive disease during immunotherapy for non–small cell lung Cancer. JAMA Oncol. 2020. https://doi.org/10.1001/jamaoncol.2020.1634 .
Tazdait M, Mezquita L, Lahmar J, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018;88:38–47. https://doi.org/10.1016/j.ejca.2017.10.017 .
doi: 10.1016/j.ejca.2017.10.017
pubmed: 29182990
Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348(25):2500–7. https://doi.org/10.1056/NEJMoa022136 .
doi: 10.1056/NEJMoa022136
pubmed: 12815135
Ambrosini V, Fanti S, Chengazi VU, Rubello D. Diagnostic accuracy of FDG PET/CT in mediastinal lymph nodes from lung cancer. Eur J Radiol. 2014;83(8):1301–2. https://doi.org/10.1016/j.ejrad.2014.04.035 .
doi: 10.1016/j.ejrad.2014.04.035
pubmed: 24917223
Zhang J, Zhao X, Zhao Y, et al. Value of pre-therapy 18F-FDG PET/CT radiomics in predicting EGFR mutation status in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47(5):1137–46. https://doi.org/10.1007/s00259-019-04592-1 .
doi: 10.1007/s00259-019-04592-1
pubmed: 31728587
Ruan M, Liu L, Wang L, et al. Correlation between combining 18F–FDG PET/CT metabolic parameters and other clinical features and ALK or ROS1 fusion in patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. January 2020. https://doi.org/10.1007/s00259-019-04652-6 .
Wang Y, Zhao N, Wu Z, et al. New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04500-7 .
Nestle U, Schimek-Jasch T, Kremp S, et al. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol. 2020;21(4):581–92. https://doi.org/10.1016/S1470-2045(20)30013-9 .
doi: 10.1016/S1470-2045(20)30013-9
pubmed: 32171429
van Diessen J, De Ruysscher D, Sonke JJ, et al. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). Radiother Oncol. 2019;131:166–73. https://doi.org/10.1016/j.radonc.2018.09.019 .
doi: 10.1016/j.radonc.2018.09.019
pubmed: 30327236
Cooke S, De Ruysscher D, Reymen B, Lambrecht M, Fredberg Persson G, Faivre-Finn C, Dieleman E, Lewensohn R, Van Diessen J, Sikorska K, Lalezari F, Sonke J, Belderbos J. OC-0609: The PET-boost trial: isotoxic homogeneous or FDG-directed dose escalation in stage II-III NSCLC. Radiotherapy and Oncology 2020;152:S345–6.
Kong F-M, Ten Haken RK, Schipper M, et al. Effect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non–small-cell lung cancer. JAMA Oncol. 2017;3(10):1358. https://doi.org/10.1001/jamaoncol.2017.0982 .
doi: 10.1001/jamaoncol.2017.0982
pubmed: 28570742
pmcid: 5674997
Lieverse RIY, Van Limbergen EJ, Oberije CJG, et al. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC Cancer. 2020;20(1):557. https://doi.org/10.1186/s12885-020-07055-1 .
doi: 10.1186/s12885-020-07055-1
pubmed: 32539805
pmcid: 7296663
Seban RD, Mezquita L, Berenbaum A, et al. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. November 2019. https://doi.org/10.1007/s00259-019-04615-x .
Chin AL, Kumar KA, Guo HH, et al. Prognostic value of pretreatment FDG-PET parameters in high-dose image-guided radiotherapy for oligometastatic non-small-cell lung cancer. Clin Lung Cancer. 2018;19(5):e581–8. https://doi.org/10.1016/j.cllc.2018.04.003 .
doi: 10.1016/j.cllc.2018.04.003
pubmed: 29759331
Mu W, Tunali I, Gray JE, Qi J, Schabath MB, Gillies RJ. Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04625-9 .
Cremonesi M, Gilardi L, Ferrari ME, et al. Role of interim 18F-FDG-PET/CT for the early prediction of clinical outcomes of Non-Small Cell Lung Cancer (NSCLC) during radiotherapy or chemo-radiotherapy. A systematic review. Eur J Nucl Med Mol Imaging. 2017;44(11):1915–27. https://doi.org/10.1007/s00259-017-3762-9 .
doi: 10.1007/s00259-017-3762-9
pubmed: 28681192
Usmanij EA, de Geus-Oei LF, Troost EG, et al. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. J Nucl Med. 2013;54(9):1528–34. https://doi.org/10.2967/jnumed.112.116921 .
doi: 10.2967/jnumed.112.116921
pubmed: 23864719
Roengvoraphoj O, Wijaya C, Eze C, et al. Analysis of primary tumor metabolic volume during chemoradiotherapy in locally advanced non-small cell lung cancer. Strahlenther Onkol. 2017. https://doi.org/10.1007/s00066-017-1229-3 .
Roengvoraphoj O, Eze C, Wijaya C, et al. How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience. Eur J Nucl Med Mol Imaging. 2018;45(12):2103–9. https://doi.org/10.1007/s00259-018-4063-7 .
doi: 10.1007/s00259-018-4063-7
pubmed: 29876620
Unterrainer M, Eze C, Ilhan H, et al. Recent advances of PET imaging in clinical radiation oncology. Radiat Oncol. 2020;15(1):1–15. https://doi.org/10.1186/s13014-020-01519-1 .
doi: 10.1186/s13014-020-01519-1
Ohri N, Bodner WR, Halmos B, et al. 18F-fluorodeoxyglucose/positron emission tomography predicts patterns of failure after definitive chemoradiation therapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2017;97(2):372–80. https://doi.org/10.1016/j.ijrobp.2016.10.031 .
doi: 10.1016/j.ijrobp.2016.10.031
pubmed: 28068244
Machtay M, Duan F, Siegel BA, et al. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol. 2013;31(30):3823–30. https://doi.org/10.1200/JCO.2012.47.5947 .
doi: 10.1200/JCO.2012.47.5947
pubmed: 24043740
pmcid: 3795891
van Diessen JNA, La Fontaine M, van den Heuvel MM, et al. Local and regional treatment response by (18)FDG-PET-CT-scans 4weeks after concurrent hypofractionated chemoradiotherapy in locally advanced NSCLC. Radiother Oncol. 2020;143:30–6. https://doi.org/10.1016/j.radonc.2019.10.008 .
doi: 10.1016/j.radonc.2019.10.008
pubmed: 31767474
Gensheimer MF, Hong JC, Chang-Halpenny C, et al. Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. Radiother Oncol. 2017;125(2):338–43. https://doi.org/10.1016/j.radonc.2017.08.007 .
doi: 10.1016/j.radonc.2017.08.007
pubmed: 28830717
Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35(13):1773–1782.
Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC. Predictive value of early 18 F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging. 2015;42(3):386–96.
doi: 10.1007/s00259-014-2944-y
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(SUPPL. 1). https://doi.org/10.2967/jnumed.108.057307 .
Cho SY, Lipson EJ, Im H-J, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET/CT imaging in patients with advanced melanoma. J Nucl Med. 2017;58(9):1421–8.
doi: 10.2967/jnumed.116.188839
Anwar H, Sachpekidis C, Winkler J, et al. Absolute number of new lesions on 18 F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. Eur J Nucl Med Mol Imaging. 2018;45(3):376–83.
doi: 10.1007/s00259-017-3870-6
Sachpekidis C, Anwar H, Winkler J, et al. The role of interim 18 F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. Eur J Nucl Med Mol Imaging. 2018;45(8):1289–96.
doi: 10.1007/s00259-018-3972-9
Rossi G, Bauckneht M, Genova C, et al. Comparison between 18F-FDG-PET- and CT-based criteria in non-small cell lung cancer (NSCLC) patients treated with Nivolumab. J Nucl Med. 2019;119:233056. https://doi.org/10.2967/jnumed.119.233056 .
doi: 10.2967/jnumed.119.233056
Kaira K, Higuchi T, Naruse I, et al. Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC. Eur J Nucl Med Mol Imaging. 2018;45(1):56–66. https://doi.org/10.1007/s00259-017-3806-1 .
doi: 10.1007/s00259-017-3806-1
pubmed: 28828507
Spigel DR, Chaft JE, Gettinger S, et al. FIR: efficacy, safety, and biomarker analysis of a phase II open-label study of atezolizumab in PD-L1–selected patients with NSCLC. J Thorac Oncol. 2018;13(11):1733–42. https://doi.org/10.1016/j.jtho.2018.05.004 .
doi: 10.1016/j.jtho.2018.05.004
pubmed: 29775807
pmcid: 7455890
Humbert O, Cadour N, Paquet M, et al. 18FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. Eur J Nucl Med Mol Imaging. 2020;47(5):1158–67. https://doi.org/10.1007/s00259-019-04573-4 .
doi: 10.1007/s00259-019-04573-4
pubmed: 31760467
Roengvoraphoj O, Gjika A, Mille E, et al. The impact of residual metabolic primary tumor volume after completion of thoracic irradiation in patients with inoperable stage III NSCLC. J Clin Oncol. 2020;38(15_suppl):9049. https://doi.org/10.1200/JCO.2020.38.15_suppl.9049 .
Martins F, Sofiya L, Sykiotis GP, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–80. https://doi.org/10.1038/s41571-019-0218-0 .
doi: 10.1038/s41571-019-0218-0
pubmed: 31092901
Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–74. https://doi.org/10.1093/annonc/mdv623 .
doi: 10.1093/annonc/mdv623
pubmed: 26715621
Wang PF, Chen Y, Song SY, et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017;8:730. https://doi.org/10.3389/fphar.2017.00730 .
doi: 10.3389/fphar.2017.00730
pubmed: 29093678
pmcid: 5651530
Topalian SL, Hodi FS, Brahmer JR, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMA Oncol. 2019;5(10):1411–20. https://doi.org/10.1001/jamaoncol.2019.2187 .
doi: 10.1001/jamaoncol.2019.2187
pubmed: 31343665
pmcid: 6659167
Rossi S, Toschi L, Castello A, Grizzi F, Mansi L, Lopci E. Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. Eur J Nucl Med Mol Imaging. 2017;44(13):2310–25. https://doi.org/10.1007/s00259-017-3802-5 .
doi: 10.1007/s00259-017-3802-5
pubmed: 28815334
Tsai KK, Pampaloni MH, Hope C, et al. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer. 2016;4:1. https://doi.org/10.1186/s40425-016-0162-9 .
doi: 10.1186/s40425-016-0162-9
pmcid: 5123387
Wachsmann JW, Ganti R, Peng F. Immune-mediated disease in ipilimumab immunotherapy of melanoma with FDG PET-CT. Acad Radiol. 2017;24(1):111–5. https://doi.org/10.1016/j.acra.2016.08.005 .
doi: 10.1016/j.acra.2016.08.005
pubmed: 27818005
Nobashi T, Baratto L, Reddy SA, et al. Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET/CT. Clin Nucl Med. 2019;44(4):e272–9. https://doi.org/10.1097/RLU.0000000000002453 .
doi: 10.1097/RLU.0000000000002453
pubmed: 30688730
Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016;2(10):1346–53. https://doi.org/10.1001/jamaoncol.2016.1051 .
doi: 10.1001/jamaoncol.2016.1051
pubmed: 27367787
Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non-small cell lung cancer. JAMA Oncol. 2018;4(3):374–8. https://doi.org/10.1001/jamaoncol.2017.2925 .
doi: 10.1001/jamaoncol.2017.2925
pubmed: 28975219
Nishino M, Hatabu H, Hodi FS. Imaging of cancer immunotherapy: current approaches and future directions. Radiology. 2019;290(1):9–22. https://doi.org/10.1148/radiol.2018181349 .
doi: 10.1148/radiol.2018181349
pubmed: 30457485
Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278(2):563–77. https://doi.org/10.1148/radiol.2015151169 .
doi: 10.1148/radiol.2015151169
pubmed: 26579733
Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749–62. https://doi.org/10.1038/nrclinonc.2017.141 .
doi: 10.1038/nrclinonc.2017.141
pubmed: 28975929
Polverari G, Ceci F, Bertaglia V, et al. 18F-FDG pet parameters and radiomics features analysis in advanced nsclc treated with immunotherapy as predictors of therapy response and survival. Cancers (Basel). 2020;12:5. https://doi.org/10.3390/cancers12051163 .
doi: 10.3390/cancers12051163
Valentinuzzi D, Vrankar M, Boc N, et al. FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab. Radiol Oncol. 2020;54(3):285–94. https://doi.org/10.2478/raon-2020-0042 .
doi: 10.2478/raon-2020-0042
pubmed: 32726293
pmcid: 7409607
Bi WL, Hosny A, Schabath MB, et al. Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin. 2019;69(2):127–57. https://doi.org/10.3322/caac.21552 .
doi: 10.3322/caac.21552
pubmed: 30720861
pmcid: 6403009
Rabbani M, Kanevsky J, Kafi K, Chandelier F, Giles FJ. Role of artificial intelligence in the care of patients with nonsmall cell lung cancer. Eur J Clin Investig. 2018;48(4):e12901. https://doi.org/10.1111/eci.12901 .
doi: 10.1111/eci.12901
Sun W, Jiang M, Dang J, Chang P, Yin FF. Effect of machine learning methods on predicting NSCLC overall survival time based on Radiomics analysis. Radiat Oncol. 2018;13(1):197. https://doi.org/10.1186/s13014-018-1140-9 .
doi: 10.1186/s13014-018-1140-9
pubmed: 30290849
pmcid: 6173915
Rahmim A, Lodge MA, Karakatsanis NA, et al. Dynamic whole-body PET imaging: principles, potentials and applications. Eur J Nucl Med Mol Imaging. 2019;46(2):501–18. https://doi.org/10.1007/s00259-018-4153-6 .
doi: 10.1007/s00259-018-4153-6
pubmed: 30269154
Pantel AR, Viswanath V, Daube-Witherspoon ME, et al. PennPET explorer: human imaging on a whole-body imager. J Nucl Med. 2020;61(1):144–51. https://doi.org/10.2967/jnumed.119.231845 .
doi: 10.2967/jnumed.119.231845
pubmed: 31562224
pmcid: 6954463
Pantel AR, Viswanath V, Karp JS. Update on the PennPET explorer: a whole-body imager with scalable axial field-of-view. PET Clin. 2021;16(1):15–23. https://doi.org/10.1016/j.cpet.2020.09.002 .
doi: 10.1016/j.cpet.2020.09.002
pubmed: 33218602
Surti S, Pantel AR, Karp JS. Total Body PET: Why, how, what for? IEEE Trans Radiat Plasma Med Sci. 2020;4(3):283–92. https://doi.org/10.1109/trpms.2020.2985403 .
doi: 10.1109/trpms.2020.2985403
pubmed: 33134653
pmcid: 7595297
Natarajan A, Mayer AT, Reeves RE, Nagamine CM, Gambhir SS. Development of novel immunoPET tracers to image human PD-1 checkpoint expression on tumor-infiltrating lymphocytes in a humanized mouse model. Mol Imaging Biol. 2017;19(6):903–14.
doi: 10.1007/s11307-017-1060-3
Natarajan A, Mayer AT, Xu L, Reeves RE, Gano J, Gambhir SS. Novel radiotracer for immunoPET imaging of PD-1 checkpoint expression on tumor infiltrating lymphocytes. Bioconjug Chem. 2015;26(10):2062–9.
doi: 10.1021/acs.bioconjchem.5b00318
Verhoeff SR, van den Heuvel MM, van Herpen CML, Piet B, Aarntzen EHJG, Heskamp S. Programmed cell death-1/ligand-1 PET imaging: a novel tool to optimize immunotherapy? PET Clin. 2020;15(1):35–43. https://doi.org/10.1016/j.cpet.2019.08.008 .
doi: 10.1016/j.cpet.2019.08.008
pubmed: 31735300
Niemeijer AN, Leung D, Huisman MC, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018;9:1. https://doi.org/10.1038/s41467-018-07131-y .
doi: 10.1038/s41467-018-07131-y
Bensch F, van der Veen EL, Lub-de Hooge MN, et al.
doi: 10.1038/s41591-018-0255-8
pubmed: 30478423
Larimer BM, Wehrenberg-Klee E, Dubois F, et al. Granzyme B PET imaging as a predictive biomarker of immunotherapy response. Cancer Res. 2017;77(9):2318–27.
doi: 10.1158/0008-5472.CAN-16-3346
Gibson HM, McKnight BN, Malysa A, et al. IFNγ PET imaging as a predictive tool for monitoring response to tumor immunotherapy. Cancer Res. 2018;78(19):5706–17.
doi: 10.1158/0008-5472.CAN-18-0253
Markovic SN, Galli F, Suman VJ, Nevala WK, Paulsen AM, Hung JC, Gansen DN, Erickson LA, Marchetti P, Wiseman GA, Signore A. Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study. Oncotarget. 2018 Jul 13;9(54):30268-30278. https://doi.org/10.18632/oncotarget.25666 .
Zhang C, Leighl NB, Wu YL, Zhong WZ. Emerging therapies for non-small cell lung cancer. J Hematol Oncol. 2019;12(1):1–24. https://doi.org/10.1186/s13045-019-0731-8 .
doi: 10.1186/s13045-019-0731-8